Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 45, Issue 15, Pages 3246-3256Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm020050+
Keywords
-
Categories
Funding
- NCRR NIH HHS [1P41 RR 12408-01A1] Funding Source: Medline
Ask authors/readers for more resources
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began with screening of the Glaxo-SmithKline proprietary compound collection, which identified several small-molecule inhibitors of Staphylococcus aureus FabI. Through a combination of iterative medicinal chemistry and X-ray crystal structure based design, one of these leads was developed into the novel aminopyridine derivative 9, a low micromolar inhibitor of FabI from S. aureus (IC50 = 2.4 muM) and Haemophilus influenzae (IC50 = 4.2 muM). Compound 9 has good in vitro antibacterial activity against several organisms, including S. aureus (MIC = 0.5 mug/mL), and is effective in vivo in a S. aureus groin abscess infection model in rats. Through FabI overexpressor and macromolecular synthesis studies, the mode of action of 9 has been confirmed to be inhibition of fatty acid biosynthesis via inhibition of FabI. Taken together, these results support FabI as a valid antibacterial target and demonstrate the potential of small-molecule FabI inhibitors for the treatment of bacterial infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available